Overview

The marketing authorisation for RevitaCAM has been withdrawn at the request of the marketing authorisation holder.

RevitaCAM : EPAR - Summary for the public

български (BG) (718.93 KB - PDF)
español (ES) (686.5 KB - PDF)
čeština (CS) (714.35 KB - PDF)
dansk (DA) (684.23 KB - PDF)
Deutsch (DE) (711.64 KB - PDF)
eesti keel (ET) (683.68 KB - PDF)
ελληνικά (EL) (768.88 KB - PDF)
français (FR) (689.86 KB - PDF)
italiano (IT) (684.55 KB - PDF)
latviešu valoda (LV) (711.22 KB - PDF)
lietuvių kalba (LT) (713.37 KB - PDF)
magyar (HU) (714.59 KB - PDF)
Malti (MT) (723.84 KB - PDF)
Nederlands (NL) (685.59 KB - PDF)
polski (PL) (717.45 KB - PDF)
português (PT) (685.71 KB - PDF)
română (RO) (712.26 KB - PDF)
slovenčina (SK) (717.59 KB - PDF)
slovenščina (SL) (702.25 KB - PDF)
Suomi (FI) (707.79 KB - PDF)
svenska (SV) (684.22 KB - PDF)

Product information

RevitaCAM : EPAR - Product Information

български (BG) (521.31 KB - PDF)
español (ES) (492.99 KB - PDF)
čeština (CS) (501.25 KB - PDF)
dansk (DA) (488.28 KB - PDF)
Deutsch (DE) (494.63 KB - PDF)
eesti keel (ET) (478.84 KB - PDF)
ελληνικά (EL) (553.97 KB - PDF)
français (FR) (499.63 KB - PDF)
hrvatski (HR) (551.39 KB - PDF)
íslenska (IS) (491.8 KB - PDF)
italiano (IT) (490.17 KB - PDF)
latviešu valoda (LV) (497.13 KB - PDF)
lietuvių kalba (LT) (501.29 KB - PDF)
magyar (HU) (504.12 KB - PDF)
Malti (MT) (504.9 KB - PDF)
Nederlands (NL) (350.42 KB - PDF)
norsk (NO) (352.92 KB - PDF)
polski (PL) (515.68 KB - PDF)
português (PT) (507.88 KB - PDF)
română (RO) (639.12 KB - PDF)
slovenčina (SK) (511.57 KB - PDF)
slovenščina (SL) (492.55 KB - PDF)
Suomi (FI) (486.93 KB - PDF)
svenska (SV) (488.96 KB - PDF)

Latest procedure affecting product information: T/0006

05/10/2015

RevitaCAM : EPAR - All Authorised presentations

български (BG) (164.54 KB - PDF)
español (ES) (151.74 KB - PDF)
čeština (CS) (167.53 KB - PDF)
dansk (DA) (150.89 KB - PDF)
Deutsch (DE) (151.51 KB - PDF)
eesti keel (ET) (151.17 KB - PDF)
ελληνικά (EL) (171.71 KB - PDF)
français (FR) (151.53 KB - PDF)
hrvatski (HR) (161.23 KB - PDF)
íslenska (IS) (151.73 KB - PDF)
italiano (IT) (151.41 KB - PDF)
latviešu valoda (LV) (170.63 KB - PDF)
lietuvių kalba (LT) (167.47 KB - PDF)
magyar (HU) (165.52 KB - PDF)
Malti (MT) (170.14 KB - PDF)
Nederlands (NL) (152.57 KB - PDF)
norsk (NO) (150.28 KB - PDF)
polski (PL) (169.01 KB - PDF)
português (PT) (151.93 KB - PDF)
română (RO) (168.91 KB - PDF)
slovenčina (SK) (167.51 KB - PDF)
slovenščina (SL) (157.36 KB - PDF)
Suomi (FI) (151.63 KB - PDF)
svenska (SV) (156.69 KB - PDF)

Product details

Name of medicine
RevitaCAM
Active substance
meloxicam
International non-proprietary name (INN) or common name
meloxicam
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QM01AC06

Pharmacotherapeutic group

Oxicams

Therapeutic indication

Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders in dogs.

Authorisation details

EMA product number
EMEA/V/C/002379

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Zoetis Belgium SA

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Marketing authorisation issued
23/02/2012
Revision
5

Assessment history

RevitaCAM : EPAR - Procedural steps taken and scientific information after authorisation

RevitaCAM : EPAR - Public assessment report

CVMP summary of positive opinion for RevitaCAM

This page was last updated on

How useful do you find this page?